https://pittplusme.org/study/1095
UPCI 16-054
STUDY BASICS
Do you have advanced stage non-small cell lung cancer (NSCLC) and have not previously been treated with other drugs? If so, you may be eligible to participate in a study to see if an investigational drug is safe, if it prevents your lung cancer from growing, and how long it works. Involves a screening period to see if you are eligible and up to 12 months of treatment.
IRB: STUDY19050393
- 16-054: A phase II clinical trial evaluating the safety and efficacy of durvalumab (MEDI4736) as 1st line therapy in advanced non-small cell lung cancer (NSCLC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 2
AGE:
18 and up
LOCATION:
UPMC Hillman Cancer Center - Shadyside
COMPENSATION:
NONE
SHARE STUDY
